课题基金 / 基金详情

Developmental Therapeutics Program

Developmental Therapeutics Program
发育治疗计划
批准号:
8388368
负责人:
FRANK PATRICK MCCORMICK
金额:
$0.01万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-05 至 2017-05-31

项目摘要

项目成果

FRANK PATRICK MCCORMICK的其他基金

相似基金

相关文献

中文摘要
翻译
发育治疗学项目是从更基本的细胞周期和信号传导项目演变而来的, 在海伦·迪勒家庭综合癌症中心之前的更新周期中, 支助赠款。细胞周期和信号传导计划的研究主题与识别有关 和治疗靶点的验证。其中许多靶标随后进入临床前测试 或者准备在早期临床试验中探索。新的早期临床试验部门已经创建了 一个理想的机会,有效地翻译这些主题,通过设计和分析的创新 研究协议。该计划由32名成员组成,涉及13个不同的部门, 将基础癌症生物学家和医生科学家聚集在一起,共同目标是发现和测试 癌症的新化合物和治疗策略该计划的主题是: 1)靶向信号转导途径(RTK、RAS、RAF/MAPK、PI 3'激酶和wnt) 2)靶向DNA复制和基因组完整性(细胞周期、端粒酶、HDAC) 3)血管生成 4)凋亡 5)敏感性和抗性的遗传决定因素 该计划成员的广泛专业知识将相互丰富和补充的发现, 个体研究者,总体计划目标是加速从药物发现到 更有效、毒性更低的癌症药物的批准。 该计划的研究范围从药物发现,细胞信号传导,分子病理学和生物成像, 药物基因组学,以及临床和人口科学与最近的高影响力出版物在自然, 自然医学,自然遗传学,新英格兰医学杂志,临床肿瘤学杂志,杂志 生物化学,JAMA,美国国家科学院院刊,和 《柳叶刀》该方案在方案内和方案间的比例相当大,而且不断增加。 出版物,反映了工作的专题广度和新出现的战略整合努力 的成员。在上一个预算年度,该方案共获得7,271,609美元的同行审议支助。的 计划有12%的计划内出版物和13%的计划间出版物。
英文摘要
The Developmental Therapeutics Program evolved from the more basic Cell Cycling and Signaling Program, which scored "Outstanding" in prior renewal cycles ofthis Helen Diller Family Comprehensive Cancer Center support grant. The research themes ofthe Cell Cycling and Signaling Program were related to identification and validation of therapeutic targets. Many of these targets have subsequently moved into preclinical testing or are ready to be explored in early-stage clinical trials. The new Eariy Phase Clinical Trials Unit has created an ideal opportunity to translate these themes effectively, through the design and analysis of innovative research protocols. The Program comprises 32 members involving 13 different departments and brings together basic cancer biologists and physician scientists with the common goal of discovering and testing novel compounds and treatment strategies for cancer The Program themes are: 1) Targeting signal transduction pathways (RTKs, RAS, RAF/MAPK, Pl 3' kinase, and wnt) 2) Targeting DNA replication and genome integrity (cell cycle, telomerase, HDAC) 3) Angiogenesis 4) Apoptosis 5) Genetic determinants of sensitivity and resistance The wide range of expertise ofthe Program members will mutually enrich and complement the discoveries of individual investigators with the overall Program goal being to accelerate the transition from drug discovery to the approval of more effective and less toxic drugs for patients with cancer. Research in the Program spans from drug discovery, cell signaling, molecular pathology and bioimaging to pharmacogenomics, as well as clinical and population science with recent high impact publications in Nature, Nature Medicine, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, Journal of Biological Chemistry, JAMA, Proceedings of the National Academy of Science of the United States, and The Lancet. The Program has a sizable and increasing percentage of intra- and inter-programmatic publications, which reflect the thematic breadth of the work and the emerging efforts of strategic integration of its members. The Program had $7,271,609 total peer-reviewed support for the last budget year. The Program has 12% intra-programmatic and 13% inter-programmatic publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biodesy Delta System for San Francisco Bay Area Region
New Ways of Targeting K-Ras
New Ways of Targeting K-Ras
New Ways of Targeting K-Ras
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: